Health Economics and Outcomes Research

In a recent study, researchers evaluated the role of autologous stem cell transplantation in patients with multiple myeloma in the context of novel agents.
A recent study compared a targeted therapy with standard chemotherapy for treatment-naïve ALK-positive advanced non-small cell lung cancer.
A recent cost-effectiveness analysis evaluated treatments for relapsed or refractory multiple myeloma from a United States health system perspective.
Lung cancer screening based on individual risk may save more lives than current USPSTF estimations but is less efficient in terms of cost and quality of life-years gained.
A 21-gene assay poses an overall incremental cost increase to the health care system in the short-term, despite lower rates of chemotherapy use.
Although the ASCO Value Framework can help quantify the health value and benefit of various cancer therapies, it has essential limitations for its use in the treatment of chronic lymphocytic leukemia.
A recent study found that the generic version of capecitabine has yielded less cost savings over a 3-year span than expected, which is likely a reflection of the lack of generic manufacturers entering the market.
A multikinase inhibitor used in the second-line setting for hepatocellular carcinoma offers limited increases in quality-adjusted life years.
A long-term post-hoc analysis compared the effects of three therapy regimens for the initial treatment of patients with a type of advanced-stage B-cell malignancy.
A recent report suggests that there is a steady increase in costs of FDA approved anticancer drugs over time, regardless of competition or supplemental indications.